Digital Diagnostics Global Leader: Paige Raises $100M Series-C Funding

Paige raised $100M in Serie-C on January 14, 2021, led by Casdin Capital and Johnson & Johnson. New York-based Paige was founded in 2017 by Thomas Fuchs and colleagues from the Memorial Sloan Kettering Cancer Center. Paige is on a mission to deliver new-generation clinical applications and predictive tests to empower and transform the pathologist and oncology.

The forthcoming article has more about its effective solutions, care team, and informed treatment decisions. 

Specifications of Paige

For more effective and informed treatment decisions, Paige is trying to deliver its novel technology to pathologists to enhance diagnostic productivity. Through Paige raised $100M in Series-C funding, it will accelerate its growth by building biomarkers(enabling new treatment plans), developing AI clinical applications, marketing its solutions for hospitals and labs, and hiring new employees in 2021. 

Let’s roll to know Paige’s details from its headquarters details, IPO Status, Investors, founders, and much more.

Features	Specifications
Company Name	Paige
Headquarters	New York, United States
Total Employees	101-250
Founded Date	Feb 2018
Founders	David Klimstra, Norman Selby, Peter Schuffler, Thomas Fuchs
Total Investors	8
Total Funding Amount	$220M
Last Investment	Series-C
Operating Status	Active
Legal Name	Paige.AI,Inc
Company Type	For Profit
Company Email	info@page.ai

Paige: Mission to Empower Pathologist And Oncology

The purpose-built platform of Paige offers AI solutions, clinical mission, predictive tests for better diagnostic confidence and accuracy.  Here is a list of missions Paige is working towards.

• It is looking towards building products that transform the way pathologists work and also building incredible tissue based-AI.

• Finding companions, partners, and investors that believe in their headstrong thoughts, ideas, and vision. For example, recently, in 2023, Microsoft is said to have become a partner with them, and Paige CEO recalls, “In Microsoft, we have really found a partner that shares our vision in how healthcare is going to be transformed…”.

• Paige is committed to providing safe, secure digital pathology solutions. Currently, they have access to the largest data sets and highly specialized global databases, which will accelerate the growth of their AI software.

• The cloud-based Paige platform believes in easy integration; therefore, its system easily integrates with your LIS(Laboratory Information System). It also allows access to the slide images through a web browser and an internet connection.

Incredible Solutions Paige Offer: Clinical and Pharmaceutical AI Applications

Paige platform is empowered by its novel technology, a new class of diagnostic devices, and computational pathology products. Their AI solutions provide a clear ray towards the future of pathology and oncology. The clinical and pharmaceutical solutions they provided are as follows:

• Paige AI Management: Paige provides the access to its LIS interoperability and multi-scanner integration in its secure end-to-end platform. In addition to the powerful AI application, it also has a commendable cloud storage, case management system, and image review via FullFocus.

• Paige Prostate Suite: It helps the pathologist detect suspicious foci, suspecting the tissue through gradation and quantification, and an indication of PNI in needle core biopsy.

• Paige Breast Suite: This AI suite assists the pathologist in breast cancer evaluation through breast biopsies and metastases detection in the lymph nodes itself. 

• Digital Biomarkers: Paige is primarily focusing on developing its digital biomarkers through the funding amount. They have partnered with pharmaceutical companies to build novel digital biomarkers through a range of services and co-development pipelines.

Why Partner With Paige? Commitment & Values 

Recently, Microsoft and Human Bytes have tied a partnership with Paige to advance cancer diagnostics and treatments. Microsoft’s strategic investment in Paige unveils the applauding global leadership of Paige in digital diagnostics and the further development towards cancer diagnostics and treatment. 

Human Bytes’ strategic partnership with Paige demonstrates their desire and mission to present Paige’s end-to-end digital pathology discoveries and solutions to the land of Denmark and Sweden. The revolutionary approach by Paige is reaching across the world and providing various digital pathology solutions.

As shared by the CEO of Paige (respective to a partnership with Human Bytes), “We are proud to have worked with leading healthcare systems and partners across the US and UK to advance the adoption of digital pathology and AI to support pathologists in their challenging but critical role in the cancer care continuum. We see Denmark and Sweden as the natural next frontier for continuing this global transformation, with the ultimate goal of improving patient outcomes.”

Paige’s team is full of individuals with experienced and varied background individuals, present across North America and Europe, all slogging their hours to find the right solutions and products that can transform computational pathology. Let’s meet the commitment and values preached by Paige’s platform that leads them to the zenith.

• A Team of hardworking and passionate individuals who believe in a “patient-first” approach. They invest in talent and provide their members with the opportunity to work alongside the leaders to revolutionize cancer with a built technology that improves patients’ life.

• To transform cancer diagnostics with easy and better solutions, Paige has ADEPT values together. A denotes the accountability that they hold for themselves and for others. D explains their disruptive approach, E spells as Execution-focused, P drives as patient-centric, and last T denotes Trusting.

• They believe in a diverse and modern technology stack and tools that help them approach a changing pathologist’s world and solve the future unique challenges associated with the tons of data, maintaining security and care.

Closing Thoughts

It is commendable that Paige’s computational pathology technology, in combination with the various data of digitized glass slides and corresponding reports, helps in finding out hard-to-recognize tissue patterns. Its platform, with the novel AI technology, is providing the pathologist with a deep insight into finding comprehensive solutions to various cancer cases that are multiplying day by day. 

FAQs